Shalini Sharp retired in September 2020 as the Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., a position she held since 2012. Prior to joining Ultragenyx, Ms. Sharp was Chief Financial Officer of Agenus Inc. from 2003 to 2012 and served as Interim Chief Executive Officer of Elan Corporation, PLC from 2001 to 2003. Ms. Sharp has extensive public company governance experience in the biotechnology industry. She has served as a Director and Chair of the Audit Committee at Sutro Biopharma, Inc. since 2018, and as a Director and Chair of the Audit Committee at Precision Biosciences, Inc. since 2019. She also currently serves as a Director at Neurocrine Biosciences, Inc. and Panacea Acquisition Corp. Ms. Sharp received her MBA and undergraduate degrees from Harvard University.